Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
- Conditions
- GlioblastomaSquamous Cell CarcinomaHodgkin LymphomaNon-hodgkin LymphomaBreast CancerProstate CancerGastric CancerOvarian CancerAcute LeukemiaPancreatic Cancer
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- AVM Biotechnology Inc
- Registration Number
- NCT05974410
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
Phase 1
Not yet recruiting
- Conditions
- ARDSCovid19Influenza, Human
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- AVM Biotechnology Inc
- Target Recruit Count
- 16
- Registration Number
- NCT04366115
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- AVM Biotechnology Inc
- Target Recruit Count
- 144
- Registration Number
- NCT04329728
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸UCLA Medical Center of Hematology/Oncology, Los Angeles, California, United States
News
No news found